Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial

Lars Gullestad, Svend-Aage Mortensen, Hans Eiskjær, Gerdt C Riise, Lena Mared, Oystein Bjørtuft, Björn Ekmehag, Kjell Jansson, Svein Simonsen, Einar Gude, Bengt Rundqvist, Hans E Fagertun, Dag Solbu, Martin Iversen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

63 Citationer (Scopus)

Abstract

Use of the mammalian target of rapamycin inhibitor everolimus with an accompanying reduction in calcineurin inhibitor (CNI) exposure has shown promise in preserving renal function in maintenance thoracic transplant patients, but robust, long-term data are required.
OriginalsprogEngelsk
TidsskriftTransplantation Aktuell
Vol/bind90
Udgave nummer12
Sider (fra-til)1581-9
Antal sider9
ISSN1612-7587
DOI
StatusUdgivet - 27 dec. 2010

Citationsformater